Sangamo Therapeutics, Inc. (LON:0R1D)
0.5045
+0.0045 (0.90%)
Dec 9, 2025, 7:10 PM BST
Sangamo Therapeutics Employees
Sangamo Therapeutics had 183 employees as of December 31, 2024. The number of employees decreased by 222 or -54.81% compared to the previous year.
Employees
183
Change (1Y)
-222
Growth (1Y)
-54.81%
Revenue / Employee
133.64K GBP
Profits / Employee
-442.74K GBP
Market Cap
127.20M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 183 | -222 | -54.81% |
| Dec 31, 2023 | 405 | -73 | -15.27% |
| Dec 31, 2022 | 478 | 47 | 10.90% |
| Dec 31, 2021 | 431 | 18 | 4.36% |
| Dec 31, 2020 | 413 | 59 | 16.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| Convatec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Genus | 3,190 |
| HUTCHMED (China) | 1,811 |
Sangamo Therapeutics News
- 7 days ago - Sangamo Therapeutics (SGMO) Surges on FDA Fast Track Designation for ST-503 - GuruFocus
- 7 days ago - Sangamo rises as FDA grants Fast Track status to neuropathic pain asset - Seeking Alpha
- 7 days ago - Sangamo (SGMO) Gains FDA Fast Track for Chronic Pain Treatment - GuruFocus
- 7 days ago - Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - GlobeNewsWire
- 18 days ago - Sangamo Therapeutics (SGMO) Advances Fabry Disease Therapy with FDA Rolling Submission - GuruFocus
- 18 days ago - Sangamo rises as FDA accepts rolling submission request for gene therapy - Seeking Alpha
- 18 days ago - FDA Accepts Sangamo's Request For Rolling BLA Submission For Fabry Disease Gene Therapy Candidate - Nasdaq
- 18 days ago - Sangamo (SGMO) Advances Gene Therapy for Fabry Disease with FDA Approval Process - GuruFocus